Mike Bayne

997 total citations
9 papers, 234 citations indexed

About

Mike Bayne is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mike Bayne has authored 9 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Radiology, Nuclear Medicine and Imaging, 5 papers in Pathology and Forensic Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mike Bayne's work include Lymphoma Diagnosis and Treatment (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Mike Bayne is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Mike Bayne collaborates with scholars based in United Kingdom, Australia and Netherlands. Mike Bayne's co-authors include Tim Illidge, Mark S. Cragg, Martin J. Glennie, Alison L. Tutt, Maureen A. Zivanovic, Yong Du, Valerie Lewington, Nicholas Brown, Ruth R. French and James Smart and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Mike Bayne

9 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mike Bayne United Kingdom	6	168	106	66	60	44	9	234
D S Goldstein United States	7	257 1.5×	164 1.5×	92 1.4×	74 1.2×	24 0.5×	8	316
T. Wiersma Netherlands	11	76 0.5×	81 0.8×	92 1.4×	143 2.4×	35 0.8×	25	288
H Goldenberg United States	7	319 1.9×	138 1.3×	40 0.6×	107 1.8×	46 1.0×	7	368
Esther Mena Gonzalez United States	6	166 1.0×	17 0.2×	81 1.2×	193 3.2×	41 0.9×	9	313
Linda Lundberg Switzerland	12	109 0.6×	267 2.5×	19 0.3×	287 4.8×	46 1.0×	41	338
J Beauregard United States	9	249 1.5×	99 0.9×	44 0.7×	138 2.3×	113 2.6×	13	381
Catherine Dubos‐Arvis France	8	104 0.6×	50 0.5×	348 5.3×	310 5.2×	27 0.6×	11	476
Mahesh Shivhare United Kingdom	8	53 0.3×	70 0.7×	80 1.2×	178 3.0×	33 0.8×	14	256
Maria Cristina Pirosa Switzerland	10	74 0.4×	156 1.5×	59 0.9×	119 2.0×	46 1.0×	28	305
N. Rodríguez-Spiteri Spain	8	190 1.1×	42 0.4×	171 2.6×	89 1.5×	20 0.5×	23	359

Countries citing papers authored by Mike Bayne

Since Specialization

Citations

This map shows the geographic impact of Mike Bayne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Bayne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Bayne more than expected).

Fields of papers citing papers by Mike Bayne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Bayne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Bayne. The network helps show where Mike Bayne may publish in the future.

Co-authorship network of co-authors of Mike Bayne

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Bayne. A scholar is included among the top collaborators of Mike Bayne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Bayne. Mike Bayne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Bayne, Mike, et al.. (2022). ctDNA analysis identifies clinically meaningful resistance mutations in EGFR mutated NSCLC on osimertinib: a case report. Lung Cancer. 165. S74–S75. 1 indexed citations

Kolstad, Arne, Tim Illidge, Nils Bolstad, et al.. (2020). Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances. 4(17). 4091–4101. 25 indexed citations

Manus, Michael P. Mac, Sarah Everitt, Mike Bayne, et al.. (2013). The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: Results of a prospective study with mature survival data. Radiotherapy and Oncology. 106(3). 292–298. 39 indexed citations

Illidge, Tim, Ruth Pettengell, Andrew Bates, et al.. (2013). Fractionated ⁹⁰Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology. 32(3). 212–218. 41 indexed citations

Hampson, Grace, Tim Ward, Jeff Cummings, et al.. (2010). Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Journal of Immunological Methods. 360(1-2). 30–38. 25 indexed citations

Illidge, Tim, Mike Bayne, Nicholas Brown, et al.. (2008). Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 113(7). 1412–1421. 61 indexed citations

MacManus, Michael, Mike Bayne, John Reynolds, et al.. (2007). Reproducibility of “Intelligent” Contouring of Gross Tumor Volume in Non-Small Cell Lung Cancer on PET/CT Images Using a Standardized Visual Method. International Journal of Radiation Oncology*Biology*Physics. 69(3). S154–S155. 2 indexed citations

Bayne, Mike, M Zivanovic, Yong Du, et al.. (2004). Oral Presentations 1. British Journal of Cancer. 91(S1). S8–S9. 3 indexed citations

Cragg, Mark S., Mike Bayne, Alison L. Tutt, et al.. (2004). A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood. 104(8). 2540–2542. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact